Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.52 |
| ▸ | ITGAV | P06756 | 2/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | CPB1 | P15086 | 1/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18307318 | 0.89 | FOLH1 (0.62) | FOLH1EPHX2ITGB3ITGAVEPHX1 | |
| SCHEMBL18308654 | 0.88 | FOLH1 (0.51) | FOLH1ITGB3ITGAVALDH1A1LMNA | |
| SCHEMBL15107348 | 0.86 | FOLH1 (0.78) | FOLH1 | |
| SCHEMBL17190068 | 0.86 | FOLH1 (0.58) | FOLH1EPHX2ITGB3ITGAVEPHX1 | |
| SCHEMBL12193062 | 0.82 | ATM (0.68) | FOLH1EPHX2EPHX1ATMANPEP | |
| SCHEMBL14063688 | 0.82 | FOLH1 (0.59) | FOLH1 | |
| SCHEMBL22300022 | 0.80 | FOLH1 (0.63) | FOLH1 | |
| SCHEMBL11207354 | 0.79 | ALDH1A1 (0.56) | FOLH1ALDH1A1TLR2ATMANPEP | |
| SCHEMBL8853611 | 0.79 | ALDH1A1 (0.56) | FOLH1ALDH1A1TLR2ATMANPEP | |
| SCHEMBL22299972 | 0.78 | ALB (0.54) | FOLH1EPHX2ITGB3ITGAVALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (IN) | 2016-12-15 | — | — | US | disclosed |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885EPHX2 1280/4885ITGB3 271/4885 |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885EPHX2 1280/4885ITGB3 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.